logo-loader
RNS
Novacyt SA

Novacyt S.A. - NIPT Tender Award

RNS Number : 4258Q
Novacyt S.A.
27 January 2026
 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

NIPT Tender Award

Contract signed with St George's University Hospitals NHS Foundation Trust

 

Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that its wholly owned subsidiary, Yourgene Health UK Ltd ("Yourgene") has been awarded the South West London Procurement Partnership tender for the provision of Non-Invasive Prenatal Testing ("NIPT") using Yourgene's flagship IONA® Nx NIPT Workflow (CE-IVD), for St George's University Hospitals NHS Foundation Trust, London ("St George's") following a competitive tender process.

 

Yourgene won its first contract with St George's on 23 March 2015 and since then, St George's has been using the IONA® Nx test under the St George's Antenatal Fetal Evaluation ("SAFE") brand. The SAFE test has been set up as a collaboration between the Fetal Medicine Unit and the St George's Genomics Service, which is a UKAS accredited medical laboratory. The service provides NIPT to approximately one third of the NHS (National Health Service) maternity services population in England and is also offered privately at St George's hospital.

 

The contract is for an initial two-year period from December 2025, with an option to extend for a further two years. This represents a continuation of existing business to the Company.

 

Yourgene's flagship IONA® Nx NIPT Workflow (CE-IVD) is an in vitro diagnostic device for prenatal screening which enables clinical laboratories to establish their own quality assured non-invasive prenatal screening service for Down's (Trisomy 21), Edwards' (Trisomy 18) and Patau's (Trisomy 13) syndromes, in line with UK National Screening Committee recommendations and NHS England requirements.

 

Lyn Rees, CEO of Novacyt, commented: "We are very pleased to have been awarded this contract following a competitive tender process and for St. George's continuing confidence in our capabilities. This win underpins the quality of our product and service in a market where we continue to deliver year on year double digit growth. As the sector expands and trade barriers ease, we are well-positioned to capture emerging opportunities and create long-term value. Our focus remains on operational excellence, innovation, and supporting our partners in delivering improved clinical and patient outcomes."

 

 

Contacts

 

Novacyt SA

https://novacyt.com/investors

Lyn Rees, Chief Executive Officer

 Via Walbrook PR

Steve Gibson, Chief Financial Officer 

 

 


SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)




Singer Capital Markets (Joint Broker)

+44 (0) 20 7496 3000

Phil Davies / James Fischer / Samed Ethemi




 +33 (1) 42 22 10 10
r.durgetto@allegrafinance.com / y.petit@allegrafinance.com



Walbrook PR (Financial PR & IR)

Paul McManus / Lianne Applegarth

Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7584 391 303

 +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

 

The Company is divided into three business segments:

 

Clinical

Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:

·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests

·    Precision Medicine: DPYD genotyping assay

·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

 

 

Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

·    Ranger® Technology: automated DNA sample preparation and target enrichment technology

·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

 

Research Use Only 

Range of services for the life sciences industry:

·    Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry

·    Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

 

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTEAKFKASKKEFA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read